Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Annals of Intensive Care
Published in: Annals of Intensive Care 1/2015

Open Access 01-12-2015 | Research

Important drug classes associated with potential drug–drug interactions in critically ill patients: highlights for cardiothoracic intensivists

Authors: Shadi Baniasadi, Behrooz Farzanegan, Maryam Alehashem

Published in: Annals of Intensive Care | Issue 1/2015

Login to get access

Abstract

Background

Patients in the intensive care unit (ICU) are more prone to drug–drug interactions (DDIs). The software and charts that indicate all interactions may not be proper for clinical usage. This study aimed to identify the main drug classes associated with clinically significant DDIs in cardiothoracic ICU and categorize DDIs to make cardiothoracic intensivists aware of safe medication usage.

Methods

This prospective study was conducted over 6 months in a cardiothoracic ICU of a university-affiliated teaching hospital. The presence of potential drug–drug interactions (pDDIs) was assessed by a clinical pharmacologist using Lexi-Interact database. Clinically significant pDDIs were defined according to severity and reliability rating. Interacting drug classes, mechanisms, and recommendations were identified for each interaction.

Results

From 1780 administered drugs, 496 lead to major (D) and contraindicated (X) interactions. Nine drug classes were responsible for D and/or X interactions with excellent (E) and/or good (G) reliability. Anti-infective agents (45.87 %) were the main drug classes that caused clinically significant pDDIs followed by central nervous system drugs (14.67 %). Azole antifungals as the most interacting antimicrobial agents precipitated metabolism inhibition of CYP3A substrates.

Conclusions

Clinically significant pDDIs as potential patient safety risks were prevalent in critically ill patients. The findings from current study help to improve knowledge and awareness of clinicians in this area and minimize adverse events due to pDDIs.
Literature
1.
Smithburger PL, Kane-Gill SL, Seybert AL. Drug–drug interactions in the medical intensive care unit: an assessment of frequency, severity and the medications involved. Int J Pharm Pract. 2012;20:402–8.CrossRefPubMed
2.
Kane-Gill S, Weber RJ. Principles and practices of medication safety in the ICU. Crit Care Clin. 2006;22:273–90.CrossRefPubMed
3.
May FE, Stewart RB, Cluff LE. Drug interactions and multiple drug administration. Clin Pharmacol Ther. 1977;22:322–8.PubMed
4.
Zarowitz BJ. Pharmacologic principles. In: Ayres SM, Grenvik A, Holbrook PR, hoemaker WC, editors. Textbook of critical care. 3rd ed. Philadelphia: W.B. Saunders; 1995. p. 1141–50.
5.
Zagli G, Tarantini F, Bonizzoli M, Di Filippo A, Peris A, De Gaudio AR, et al. Altered pharmacology in the intensive care unit patient. Fundam Clin Pharmacol. 2008;22:493–501.CrossRefPubMed
6.
Grizzle AJ, Mahmood MH, Ko Y, Murphy JE, Armstrong EP, Skrepnek GH, et al. Reasons provided by prescribers when overriding drug–drug interaction alerts. Am J Manag Care. 2007;13:573–8.PubMed
7.
Becker ML, Caspers PW, Kallewaard M, Bruinink RJ, Kylstra NB, Heisterkamp S, et al. Determinants of potential drug–drug interaction associated dispensing in community pharmacies in the Netherlands. Pharm World Sci. 2007;29:51–7.PubMedCentralCrossRefPubMed
8.
Sweilehe WM, Sawalhae AF, Jaradate NA. Extent of potential drug interactions among patients receiving anti-hypertensive medications. Saudi Med J. 2005;26:548–52.
9.
Ismail M, Iqbal Z, Khattak MB, Khan MI, Arsalan H, Javaid A, et al. Potential drug–drug interactions in internal medicine wards in hospital setting in Pakistan. Int J Clin Pharm. 2013;35:455–62.CrossRefPubMed
10.
Smithburger PL, Kane-Gill SL, Seybert AL. Drug–drug interactions in cardiac and cardiothoracic intensive care units: an analysis of patients in an academic medical centre in the US. Drug Saf. 2010;33:879–88.CrossRefPubMed
11.
Askari M, Eslami S, Louws M, Wierenga PC, Dongelmans DA, Kuiper RA, et al. Frequency and nature of drug–drug interactions in the intensive care unit. Pharmacoepidemiol Drug Saf. 2013;22:430–7.CrossRefPubMed
12.
Reis AM, Cassiani SH. Prevalence of potential drug interactions in patients in an intensive care unit of a university hospital in Brazil. Clinics (Sao Paulo). 2011;66:9–15.CrossRef
13.
Hammes JA, Pfuetzenreiter F, Silveira FD, Koenig A, Westphal GA. Potential drug interactions prevalence in intensive care units. Rev Bras Ter Intensiva. 2008;20:349–54.CrossRefPubMed
14.
Uijtendaal EV, van Harssel LL, Hugenholtz GW, Kuck EM, Zwart-van Rijkom JE, Cremer OL, et al. Analysis of potential drug–drug interactions in medical intensive care unit patients. Pharmacotherapy. 2014;34:213–9.CrossRefPubMed
15.
16.
McEvoy GK, Snow ED (editors). AHFS: drug information. Bethesda: American Society of Health-System Pharmacists; 2012.
17.
World Health Organization. ICD-10 classifications of mental and behavioural disorder. Geneva: Clinical Descriptions and Diagnostic Guidelines; 2015.
18.
Martinbiancho J, Zuckermann J, Dos Santos L, Silva MM. Profile of drug interactions in hospitalized children. Pharm Pract (Granada). 2007;5:157–61.CrossRef
19.
Magnus D, Rodgers S, Avery AJ. GPs’ views on computerized drug interaction alerts: questionnaire survey. J Clin Pharm Ther. 2002;27:377–82.CrossRefPubMed
20.
Pereira JM, Paiva JA. Antimicrobial drug interactions in the critically ill patients. Curr Clin Pharmacol. 2013;8:25–38.PubMed
21.
Baniasadi S, Fahimi F, Shalviri G. Developing an adverse drug reaction reporting system at a teaching hospital. Basic Clin Pharmacol Toxicol. 2008;102:408–11.CrossRefPubMed
22.
Islahudin F, Ong HY. Appropriate vancomycin use in a Malaysian tertiary hospital based on current HICPAC recommendations. J Infect Dev Ctries. 2014;8:1267–71.CrossRefPubMed
23.
Del Rosso JQ. Oral antibiotic drug interactions of clinical significance to dermatologists. Dermatol Clin. 2009;27:91–4.CrossRefPubMed
24.
Mignat C. Clinically significant drug interactions with new immunosuppressive agents. Drug Saf. 1997;16:267–78.CrossRefPubMed
25.
Smithburger PL, Seybert AL, Armahizer MJ, Kane-Gill SL. QT prolongation in the intensive care unit: commonly used medications and the impact of drug–drug interactions. Expert Opin Drug Saf. 2010;9:699–712.CrossRefPubMed
26.
John LJ, Devi P, John J, Arifulla M, Guido S. Utilization patterns of central nervous system drugs: a cross-sectional study among the critically ill patients. J Neurosci Rural Pract. 2011;2:119–23.PubMedCentralCrossRefPubMed
27.
Lima RE, De Bortoli Cassiani SH. Potential drug interactions in intensive care patients at a teaching hospital. Rev Lat Am Enfermagem. 2009;17:222–7.CrossRefPubMed
28.
Lexicomp online®, Carbamazepine: drug information. Hudson: Lexi-Comp, Inc.; 2015.
29.
Kindler CH, Verotta D, Gray AT, Gropper MA, Yost CS. Additive inhibition of nicotinic acetylcholine receptors by corticosteroids and the neuromuscular blocking drug vecuronium. Anesthesiology. 2000;92:821–32.CrossRefPubMed
30.
Murray MJ, Cowen J, DeBlock H, Erstad B, Gray AW Jr, Tescher AN, Task Force of the American College of Critical Care Medicine (ACCM) of the Society of Critical Care Medicine (SCCM), American Society of Health-System Pharmacists, American College of Chest Physicians, et al. Clinical practice guidelines for sustained neuromuscular blockade in the adult critically ill patient. Crit Care Med. 2002;30:142–56.CrossRefPubMed
31.
Lexicomp online®, Amiodarone: drug information. Hudson: Lexi-Comp, Inc.; 2015.
32.
33.
Johnson MD, Hamilton CD, Drew RH, Sanders LL, Pennick GJ, Perfect JR. A randomized comparative study to determine the effect of omeprazole on the peak serum concentration of itraconazole oral solution. J Antimicrob Chemother. 2003;51:453–7.CrossRefPubMed
34.
Krag M, Perner A, Wetterslev J, Møller MH. Stress ulcer prophylaxis in the intensive care unit: is it indicated? A topical systematic review. Acta Anaesthesiol Scand. 2013;57:835–47.CrossRefPubMed
35.
Krag M, Perner A, Wetterslev J, Wise MP, Borthwick M, Bendel S, et al. Stress ulcer prophylaxis in the intensive care unit: an international survey of 97 units in 11 countries. Acta Anaesthesiol Scand. 2015;59:576–85.CrossRefPubMed
36.
Frew JW. The clinical significance of drug interactions between dermatological and psychoactive medications. Dermatol Ther. 2014;27:1–11.CrossRefPubMed
37.
Manitpisitkul W, McCann E, Lee S, Weir MR. Drug interactions in transplant patients: what everyone should know. Curr Opin Nephrol Hypertens. 2009;18:404–11.CrossRefPubMed
38.
Amundsen R, Christensen H, Zabihyan B, Asberg A. Cyclosporine A, but not tacrolimus, shows relevant inhibition of organic anion-transporting protein 1B1-mediated transport of atorvastatin. Drug Metab Dispos. 2010;38:1499–504.CrossRefPubMed
39.
Wunsch H, Rowan KM, Angus DC. International comparisons in critical care: a necessity and challenge. Curr Opin Crit Care. 2007;13:725–31.CrossRefPubMed
40.
41.
Oshikoya KA, Oreagba IA, Ogunleye OO, Lawal S, Senbanjo IO. Clinically significant interactions between antiretroviral and co-prescribed drugs for HIV-infected children: profiling and comparison of two drug databases. Ther Clin Risk Manag. 2013;9:215–21.PubMedCentralCrossRefPubMed
42.
Paw H, Shulman R. Handbook of drugs in intensive care: an A-Z guide. 4th ed. New York: Cambridge University; 2010.CrossRef
43.
Young P. Intensive care unit drug manual, 2nd ed. Wellington, New Zealand; 2013
Metadata
Title
Important drug classes associated with potential drug–drug interactions in critically ill patients: highlights for cardiothoracic intensivists
Authors
Shadi Baniasadi
Behrooz Farzanegan
Maryam Alehashem
Publication date
01-12-2015
Publisher
Springer Paris
Published in
Annals of Intensive Care / Issue 1/2015
Electronic ISSN: 2110-5820
DOI
https://doi.org/10.1186/s13613-015-0086-4

Other articles of this Issue 1/2015

Annals of Intensive Care 1/2015 Go to the issue

Research

Sonographic chest B-lines anticipate elevated B-type natriuretic peptide level, irrespective of ejection fraction

Research

Development and usability testing of a Web-based decision aid for families of patients receiving prolonged mechanical ventilation

Research

Associations between bolus infusion of hydrocortisone, glycemic variability and insulin infusion rate variability in critically Ill patients under moderate glycemic control

Review

Hyperoxia in intensive care, emergency, and peri-operative medicine: Dr. Jekyll or Mr. Hyde? A 2015 update

Research

Screening of patients with augmented renal clearance in ICU: taking into account the CKD-EPI equation, the age, and the cause of admission

Research

Admission vitamin D status is associated with discharge destination in critically ill surgical patients